MedTrace Logo

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

NCT06209619 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-02-27

No results posted yet for this study

Summary

This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal response early on to CAR T-cell therapy. Immunotherapy with CC-99282 may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving CC-99282 with rituximab may be a safe and effective treatment option for patients who have received CAR-T cell therapy for relapsed or refractory non-Hodgkin's lymphoma.

Conditions

  • B-Cell Non-Hodgkin Lymphoma-Recurrent
  • Diffuse Large B-Cell Lymphoma-Recurrent
  • Follicular Lymphoma-Recurrent
  • High Grade B-Cell Lymphoma-Recurrent
  • Primary Mediastinal Large B-Cell Lymphoma-Recurrent
  • Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent
  • B-Cell Non-Hodgkin Lymphoma-Refractory
  • Diffuse Large B-Cell Lymphoma-Refractory
  • Follicular Lymphoma-Refractory
  • High Grade B-Cell Lymphoma-Refractory
  • Primary Mediastinal Large B-Cell Lymphoma-Refractory
  • Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory

Interventions

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

Golcadomide

Given PO

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

BIOLOGICAL

Rituximab

Given IV

Sponsors & Collaborators

Principal Investigators

  • Nathan Denlinger, DO, MS · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-29
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06209619 on ClinicalTrials.gov